The recently listed company’s investors get déjà vu with the first human data from a trial of the allogeneic cell therapy CB-010.
Positive data result in positive share price movements – something of a novelty in the current market.
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
Though broad questions intensify, NTLA-2001 continues showing clinically what it is meant to.
Novel approaches including gene editing are creeping towards approval.
But the pace of biopharma asset deals dips. Are the two trends related?
US clinical hold over Allogene’s entire pipeline has just been lifted.